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Abstract
Background: A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium
falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the
most efficient long-lasting protection against a homologous parasite. However, parasite genetic diversity is a major
hurdle for protection against heterologous strains.
Methods: We conducted a double-blind, randomized controlled trial in 39 healthy participants of NF54-CPS
immunization by bites of 45 NF54-infected (n = 24 volunteers) or uninfected mosquitoes (placebo; n = 15 volunteers)
against a controlled human malaria infection with the homologous NF54 or the genetically distinct NF135.C10 and
NF166.C8 clones. Cellular and humoral immune assays were performed as well as genetic characterization of the
parasite clones.
Results: NF54-CPS immunization induced complete protection in 5/5 volunteers against NF54 challenge infection at
14 weeks post-immunization, but sterilely protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8
challenge infection, respectively. Post-immunization plasma showed a significantly lower capacity to block heterologous
parasite development in primary human hepatocytes compared to NF54. Whole genome sequencing showed that
NF135.C10 and NF166.C8 have amino acid changes in multiple antigens targeted by CPS-induced antibodies. Volunteers
protected against heterologous challenge were among the stronger immune responders to in vitro parasite stimulation.
Conclusions: Although highly protective against homologous parasites, NF54-CPS-induced immunity is less effective
against heterologous parasite clones both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine
approaches require more potent immune responses for heterologous protection.
Trial registration: This trial is registered in clinicaltrials.gov, under identifier NCT02098590.
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Background
Malaria has a significant impact on human health and
economic welfare worldwide. In 2015, it caused over 200
million cases of disease and nearly half a million deaths
[1]. Despite a significant decrease in malaria deaths hav-
ing been observed in the last 15 years [1], the emergence
of insecticide-resistant mosquitoes [2] and drug-resistant
parasites [3] are threatening malaria control efforts,
highlighting the need for a highly effective vaccine.
While naturally acquired immunity likely never results
in sterile protection against the parasite [4], generation
of long-lasting and sterilizing immunity against malaria
is the goal of pre-erythrocytic vaccine approaches. So
far, only one sub-unit vaccine, RTS,S (Mosquirix, Glaxo
Smith Kline), has been recommended for defined clinical
application [5]. This vaccine is based on a major sporo-
zoite surface protein, the circumsporozoite protein
(CSP), and has been shown to induce a short-term, 30–
50% efficacy in reducing the incidence of clinical malaria
in endemic areas, as well as in the controlled human
malaria infection (CHMI) model [6–8]. Sterilizing im-
munity can be induced by attenuated whole sporozoite
approaches. Immunization with radiation-attenuated
sporozoites requires bites of at least 1000 infected mos-
quitoes to induce sterile protection in 50% of volunteers
[9], or a total dose of 675 k cryopreserved sporozoites
injected intravenously for full homologous protection
[10]. In contrast, bites by only 30–45 malaria-infected
mosquitoes [11, 12] or 150 k intravenously injected cryo-
preserved sporozoites [13] in the chemoprophylaxis and
sporozoite (CPS) regimen induces complete sterile pro-
tection against the homologous parasite. CPS-induced
protection can last for at least 2.5 years, showing unpre-
cedented efficiency and sustainability of the protective
immune response [14]. Specifically, strong effector
memory T cell responses are induced [11, 12], as well as
memory B cell and antibody responses targeting pre-
erythrocytic stage antigens with functional activity
against homologous sporozoites, inhibiting parasite
development in liver cells in vitro and in vivo in human
liver-chimeric mice [15–17].
Despite these advances, a major hurdle for the induc-
tion of protection against heterologous strains is the
well-known genetic diversity of Plasmodium falciparum,
allowing parasite evasion and reducing the protective ef-
ficacy. More recently, immunization with radiation-
attenuated sporozoites provided 53% protection against
a heterologous challenge [18]. There is also incidental
evidence for CPS-induced heterologous protection in
the CHMI model [19], but this has not been systematic-
ally addressed.
Here, we describe the first double-blind, placebo-
controlled CHMI trial of NF54-CPS immunization by a
total of 45 P. falciparum NF54-infected mosquitoes
followed by a challenge infection with either P. falcip-
arum NF135.C10 clone from Cambodia or NF166.C8
clone from Guinea. Parasites were characterized by
whole genome sequencing and CPS-induced cellular and
humoral responses were analyzed.
Methods
Study design and participants
This single center, double-blind, randomized, placebo-
controlled trial was conducted at the Radboud university
medical center (Nijmegen, The Netherlands) between
February and November 2015. Study participants were
healthy male and female volunteers (18–35 years old)
with no history of malaria and screened for eligibility, in-
cluding a complete medical and family history, physical
examination, blood hematological and biochemical pa-
rameters, and serology for HIV, hepatitis B and C, and
the asexual stages of P. falciparum as previously de-
scribed [20]. All candidate participants provided written
informed consent at the screening visit.
Study approval
The study was approved by the Central Committee for
Research Involving Human Subjects of The Netherlands
(CCMO NL48732.091.14) and conducted according to
the principles outlined in the Declaration of Helsinki
and Good Clinical Practice standards. This trial is regis-
tered at ClinicalTrials.gov, identifier NCT02098590.
Procedures
All included study subjects (n = 41, Fig. 1) received
chloroquine in a prophylactic dose (i.e., a loading dose
of 300 mg of chloroquine on each of the first 2 days,
followed by 300 mg once a week), for a total duration of
13 weeks. While under chloroquine prophylaxis, study
groups 1, 2 and 3 received three immunizations with
bites of 15 P. falciparum NF54-infected Anopheles ste-
phensi mosquitoes. Groups 4, 5 and 6 received three
mock immunizations with bites of 15 uninfected
mosquitoes.
Volunteers were followed on an outpatient basis from
days 6 to 10 after each immunization. Blood was exam-
ined daily, including hemocytometry, white-blood cell
counts, lactic acid dehydrogenase, and highly sensitive
troponin-T. From day 7 to 9, blood was also checked for
malaria parasites by thick blood smear microscopy and
quantitative real-time PCR (qPCR) was performed retro-
spectively (after study de-blinding), as described previ-
ously [21, 22].
At 14 weeks after discontinuation of chloroquine
prophylaxis, all participants were exposed to bites of five
P. falciparum-infected A. stephensi mosquitoes (Table 1).
Subjects of groups 1 and 4 were challenged with the
heterologous NF135.C10 clone, groups 2 and 5 with the
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heterologous NF166.C8 clone, and groups 3 and 6 with
the homologous NF54 strain. Mosquitoes were
examined to verify that a blood meal was taken and the
presence of sporozoites in mosquito salivary glands was
confirmed by dissection. If insufficient infected mosqui-
toes had taken a blood meal, subjects were exposed to
additional mosquitoes.
After challenge infection, subjects visited the clinical
trial site twice daily from day 6 to day 15 and once daily
from day 16 until day 21. Blood was drawn for parasito-
logical assessments at every visit and safety laboratory
measurements were performed once daily as described
above. Malaria symptoms, including fever, headache,
malaise, fatigue, myalgia, arthralgia, nausea, vomiting,
chills, diarrhea, and abdominal pain, were solicited. All
signs and symptoms (solicited and unsolicited) were
recorded and graded by the attending physician as mild
(easily tolerated), moderate (interferes with normal activ-
ity), or severe (prevents normal activity) or, in case of
fever, as grade 1 (>37.5 °C to 38.0 °C), grade 2 (38.1 °C
to 39.0 °C), or grade 3 (> 39.0 °C).
Subjects were treated with a curative regimen of
1000 mg atovaquone and 400 mg proguanil once daily
for 3 days when parasitemia above the treatment thresh-
old (100 parasites per milliliter of blood) was detected
by qPCR [22]. Subjects that remained qPCR negative
Fig. 1 Clinical trial profile
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were presumptively treated with the same regimen
28 days after challenge infection. Complete cure was
confirmed by two consecutive negative qPCR measure-
ments after treatment.
Randomization and masking
All study subjects, in two time-separated cohorts, were
randomly allocated to one of the six study groups using a
computer-generated list of random numbers (Microsoft
Excel 2007, Redmond, WA, USA), with study groups
stratified equally over each cohort. Randomization was
prepared by two independent investigators and was stored
securely, in sealed opaque envelopes with restricted
access. Subjects, investigators and primary outcome asses-
sors were masked to group assignment.
During the study, the homologous (NF54) challenge
strain infection of the second cohort was delayed as
there was no sufficiently infected batch of mosquitoes
available (> 40% infected; according to our standard
operating procedures). Challenge strain blinding had to
be lifted for this group (six subjects), allowing them to
be challenged 2 weeks later. The investigators remained
blinded to immunization allocation of all participants
and to the challenge strain allocation of the NF135.C10
and NF166.C8 groups until the end of the study. All
study subjects and immunology assessors remained
blinded during the entire study. The partial de-blinding
procedure was documented and reported to the Central
Committee for Research Involving Human Subjects of
The Netherlands.
Primary study outcome
The primary outcome was the pre-patent period, namely
time to parasitemia (a single qPCR measurement with a
parasite density greater than 100 parasites per milliliter
of blood) in subjects after challenge infection. Study
sample size was determined in order to be able to detect
a difference in pre-patent period of 3 days between the
immunization and control groups (with α = 0.05, power
= 0.90).
Parasites
NF54 is a longstanding and well-characterized strain iso-
lated several decades ago from a person with airport mal-
aria near Schiphol Airport (Amsterdam, The Netherlands)
and likely originating from West Africa [23]. The
NF135.C10 clone originated from a clinical isolate in
Cambodia [24]. The NF166.C8 clone originated from a pa-
tient after a recent visit to Guinea (West Africa) [25].
Parasite culture and generation of infected mosquitoes
P. falciparum NF54, NF135.C10, and NF166.C8 asexual
and sexual blood stages were cultured in a semi-
automated culture system [26–29]. A. stephensi mosqui-
toes for immunizations and challenge infections were
reared in the Radboud university medical center insectary
(Nijmegen, The Netherlands) according to standard oper-
ating procedures. Infected mosquitoes were obtained by
standard membrane feeding on gametocyte cultures of the
different strains as described previously [29].
For in vitro sporozoite infectivity assays, salivary
glands from infected A. stephensi mosquitoes were hand
dissected and collected in complete William’s B culture
medium without serum. Salivary glands were homoge-
nized in a homemade glass grinder and the number of P.
falciparum sporozoites was counted in a Bürker-Türk
counting chamber using phase contrast microscopy [15].
Plasma samples
Citrated plasma samples were collected from 24 CPS-
immunized volunteers at different time points using
citrated vacutainer cell preparation tubes (CPT vacutai-
ners; Becton Dickinson). Samples collected 11–14 days
before the first CPS immunization (pre-immunization)
and 1 day before challenge infection (18 weeks after the
last immunization; post-immunization) were used for
analysis of malaria antigen-specific antibody levels and
Table 1 Baseline characteristics of subjects included in the analysis
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Number of participants (n = 39) 10 9 5 5 5 5
Sex
Male 3 (30%) 2 (22%) 2 (40%) 3 (60%) 2 (40%) 5 (100%)
Female 7 (70%) 7 (78%) 3 (60%) 2 (40%) 3 (60%) 0 (0%)
Age, years 21.5 (1.8) 21.1 (2.6) 22.4 (1.6) 20.1 (1.3) 20.4 (2.5) 22.6 (3.1)
Body mass index, kg/m2 21.8 (2.3) 21.4 (1.7) 22.0 (3.1) 20.6 (2.0) 24.8 (3.3) 23.2 (1.7)
P. falciparum strain
Immunization NF54 NF54 NF54 Uninfected Uninfected Uninfected
Challenge NF135.C10 NF166.C8 NF54 NF135.C10 NF166.C8 NF54
Data are n (%), mean (SD)
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assessment of functional activity in vitro. Plasma sam-
ples were stored in aliquots at – 20 °C and re-thawed no
more than three times.
Prior to use for in vitro sporozoite infectivity assays in
primary human hepatocytes, citrated plasma aliquots
were heat-inactivated for 30 minutes at 56 °C and spun
down at 13,000 rpm for 5 minutes at room temperature.
Peripheral blood mononuclear cell (PBMC) isolations and
cryopreservation
Venous whole blood was collected in CPT vacutainers at
different time points. PBMCs were isolated from periph-
eral blood samples, cryopreserved and stored as de-
scribed previously [11]. Briefly, PBMCs were isolated by
centrifugation, washed in ice-cold phosphate buffered sa-
line, and counted in 0.1% Trypan blue with 5% Zap-o-
Globin II Lytic Reagent (Beckman Coulter) to assess cell
viability. Cells were cryopreserved at a concentration of 107
PBMCs per milliliter in ice-cold fetal bovine serum (Gibco)
containing 10% dimethylsulfoxide (Merck, Germany) using
Mr. Frosty freezing containers (Nalgene). Subsequently,
PBMC samples were stored in vapor-phase nitrogen.
PBMC samples collected 11–14 days before the first CPS
immunization (pre-immunization) and 1 day before chal-
lenge infection (18 weeks after the last immunization; post-
immunization) were used for in vitro PBMC restimulation
experiments and flow cytometric analysis.
Humoral immunological assays
Malaria antigen-specific antibody levels Specific anti-
bodies to P. falciparum CSP (full-length protein, ob-
tained from Genova Biotechniques Pvt. Ltd. in
Hyderabad, India [30]) in citrated anti-coagulated
plasma samples were determined by a standardized
enzyme-linked immunosorbent assay (ELISA) at indi-
cated time points as previously described. Antibody
levels were expressed as arbitrary units (AU) in relation
to a pool of 100 sera from adults living in an area in
Tanzania where malaria is highly endemic, with this
positive control set at 100 AU [12, 17] (see also Add-
itional file 1: S1 for detailed information). ELISA data
analysis was performed with Auditable Data Analysis
and Management System for ELISA (ADAMSEL, version
1.1) as previously described [17]. Post-immunization
plasma samples were corrected for baseline responses
for CSP.
In vitro sporozoite infectivity assay of primary hu-
man hepatocytes To test CPS-induced functional anti-
body activity against sporozoite development, fresh
primary human hepatocytes were isolated and cultured
from patients undergoing partial hepatectomy as de-
scribed in Additional file 1: S2. Briefly, viable hepato-
cytes (5 × 104 hepatocytes/well) in complete William’s B
medium were seeded into 96-well flat-bottom plates
(Falcon, 353219) coated with 0.056 mg/mL rat tail colla-
gen I per well (Roche Applied Science, 11179179-001),
and cultured at 37 °C in an atmosphere of 5% CO2.
Two to three days after seeding of hepatocytes, batches
of fresh P. falciparum NF54, NF135.C10, or NF166.C8
sporozoites in Williams B medium were pre-incubated
with heat-inactivated naive human control serum (10%
final concentration) and heat-inactivated pre- or post-
CPS immunization plasma at a final concentration of
10% for 30 minutes on ice (final concentration of serum/
plasma in each sample: 20%). Sporozoites pre-incubated
with an anti-CSP monoclonal antibody (mAb 2A10,
10 μg/mL final concentration, MR4; MRA-183A) served
as a positive control. Sporozoites in the presence of 20%
heat-inactivated naive human control serum served as
standard control; 5 × 104 of pre-incubated sporozoites
were added to 96-well plates containing monolayers of
primary human hepatocytes in triplicate. Five to six days
post-infection, the number of P. falciparum-infected hepa-
tocytes was assessed by staining for P. falciparum Heat
shock protein-70 and indirect immuno-fluorescence
analysis using a Leica DMI6000B inverted microscope as
described in Additional file 1: S3 and S4.
Cellular immunological assays
For the assessment of P. falciparum-specific cellular im-
mune responses, pre- and post-immunization PBMCs from
CPS-immunized volunteers who received NF135.C10- and
NF166.C8-challenge infection were re-stimulated in vitro
with cryopreserved P. falciparum NF54-infected erythro-
cytes (PfRBCs), as described previously [11, 14] and in de-
tail in Additional file 1: S5. Briefly, after thawing, PBMCs in
complete culture medium (final concentration of 10 × 106
cells/mL) were stimulated in vitro in duplicate with either
106 cryopreserved NF54 PfRBCs or 106 uninfected erythro-
cytes (negative control) for 24 h at 37 °C with 5% CO2.
Fluorochrome-labeled monoclonal antibody to CD107a
was added for the duration of the stimulation. During the
last 4 h, 10 μg/mL Brefeldin A and 2 μM monensin were
added to the test wells, and 10 ng/mL PMA (Sigma-Al-
drich) and 1 μg/mL ionomycin were added to positive con-
trol wells.
After 24 h of stimulation in total, cells were stained
with a Live/Dead fixable dead cell stain dye and
fluorochrome-labeled antibodies against the surface
markers CD3, CD4, CD8, gamma delta T cell receptor,
and CD56, and against the intracellular cytotoxic marker
granzyme B and the cytokine interferon (IFN)-γ. Sam-
ples were kept cold and in the dark in 1% paraformalde-
hyde in phosphate buffered saline until measured by
flow cytometry on the same day. Both time points for
each volunteer were thawed, stimulated and stained
within the same experimental round. Samples were
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acquired using a 10-colour Gallios flow cytometer (Beck-
man Coulter), and single stained cells were run every
round for compensation. Data analysis was performed
using FlowJo software (Version 10.0.8, Tree Star). Unin-
fected erythrocyte responses were subtracted from
PfRBC-specific responses for every volunteer for each
time point, and post-immunization responses were
corrected for pre-immunization responses.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (version 5, GraphPad Software Inc., California,
USA). Differences in pre-patent period by qPCR between
groups were determined by Log-Rank test. Differences
in antibody levels across the immunization groups were
analyzed with one-way ANOVA with Bonferroni’s mul-
tiple comparison post-hoc correction. For analysis of
in vitro sporozoite infectivity data, differences were
tested using the paired Student’s t-test, except when
comparing between immunization groups, when a one-
way ANOVA with Bonferroni’s multiple comparison
post-hoc correction was used. A P value of < 0.05 was
considered significant.
Genetic analysis of parasites
Genomic DNA was obtained from the three study strains
and 2.3 μg of each were submitted for Illumina sequen-
cing. The resulting fastq reads (150 bp) were aligned to
the P. falciparum 3D7 reference genome (v.3, plasmoDB)
using bowtie2 software (bowtie-bio.sourceforge.net).
Single nucleotide polymorphisms (SNPs) were called with
samtools and bcf/vcftools software (samtools.sourcefor-
ge.net). An alignment of all SNPs (with bcftools quality
score > 100) was used to compare the study strains to
others from Ghana, Guinea, Kenya, Cambodia, Thailand,
and Vietnam in a combined analysis of genetic variation,
as described by Campino et al. [31]. Furthermore, genes
that were identified to elicit a humoral immune response
in CPS immunization were examined [16]. This panel of
11 pre-erythrocytic genes including CSP and LSA-1, com-
plemented by MAEBL, was checked for amino acid
changes in the translated protein.
Results
Protective efficacy of CPS immunization against
heterologous challenge
A total of 41 volunteers were included into the study, of
whom 24 immunization and 15 placebo-control volun-
teers completed the clinical trial and were included in
the per protocol analysis. One volunteer withdrew after
being unable to attend the study visits and one was ex-
cluded due to a concomitant condition (Fig. 1). The
baseline characteristics of the study population are
shown in Table 1.
As previously observed, NF54-CPS immunization in-
duced sterile protection against a homologous NF54
challenge in 5 out of 5 volunteers (Fig. 2a) [11, 12, 32].
In contrast, 2 out of 10 volunteers were sterilely pro-
tected after challenge with NF135.C10, with 6 out of 10
volunteers showing a prolonged pre-patent period
Fig. 2 Parasitemia following homologous and heterologous challenge infection. The percentage of volunteers remaining qPCR negative (Kaplan–Meier
survival proportions) after challenge infection with a homologous NF54 (n = 5 immunized; n = 5 controls) (a) or heterologous NF135.C10 (n = 10
immunized; n = 5 controls) (b) or NF166.C8 (n = 9 immunized; n = 5 controls) (c) strain is shown. Solid lines represent CPS-immunized volunteers and
dotted lines represent placebo control-immunized volunteers. ** P < 0.01 as determined by Log-rank (Mantel Cox) test
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compared to mock-immunized controls (more than two-
fold the standard deviation of controls) (Fig. 2b). After
NF166.C8 challenge, 1 out of 9 NF54-immunized volun-
teers was fully protected, while 8 out of 9 volunteers
showed no delay to patency (Fig. 2c). There was also no
difference in mean day 7 parasitemia (representing the
liver parasite burden) between immunized volunteers
and controls challenged with NF166.C8 (Additional file
2: Figure S1). In line with a previous study [25],
NF135.C10 and NF166.C8 showed higher infectivity
than NF54. Overall, NF54-CPS immunization induced
only modest protection against heterologous clones.
As a marker for the induction of immune responses,
antibody levels to the major sporozoite vaccine-target
antigen CSP [7, 8] were measured. All volunteers
showed a post-immunization CSP antibody titer as de-
termined by ELISAs and corrected for baseline (median
3.7 AU; interquartile range (IQR) 2.9–4.5), which did
not significantly differ between groups (group 1: 24.7
(IQR 10.4–45.2), group 2: 24.7 (IQR 17.0–37.1), and
group 3: 74.1 (IQR 20.9–187.0)).
In vitro inhibition of intra-hepatic sporozoite develop-
ment by CPS-induced antibodies
Next, functional antibody activity to inhibit sporozoite
development in primary human hepatocytes in vitro was
tested. Post-immunization plasma from all 24 NF54-CPS-
immunized volunteers significantly reduced homologous
intra-hepatic sporozoite development (P < 0.0001; Fig. 3a).
However, inhibition of intra-hepatic NF135.C10 and
NF166.C8 development was significantly lower (P < 0.01),
with a median percentage inhibition of 40.7% (IQR 29.6–
59.1), 26.9% (IQR 15.6–35.0), and 31.0% (IQR 22.6–43.2)
for NF54, NF135.C10, and NF166.C8 sporozoites, respect-
ively (Fig. 3b). Intra-hepatic development of both heterol-
ogous clones was equally inhibited by NF54-CPS
immunization induced antibodies (Fig. 3b). While these
in vitro data reflect the clinical outcome in vivo at group
level, individual inhibition in vitro did not correlate with
in vivo pre-patent periods and/or parasitemia (data not
shown).
Genetic diversity of NF54, NF135.C10, and N166.C8
challenge strains
The genetic diversity among P. falciparum mutants has
been shown to be a strong factor in parasite evasion of
protective immune responses. Whole genomes of the
parasite clones used in this study were sequenced. High
quality SNPs were called with about equal numbers for
NF135.C10 and NF166.C8 (Additional file 2: Table S1;
Figure S3). All polymorphisms were used to infer a phyl-
ogeny including isolates from Southeast Asia and East
and West Africa [31]. As expected, NF54 and NF166.C8
were very similar to West African isolates, while
NF135.C10 showed more resemblance to other South-
east Asian strains (Fig. 4). We next compared amino
acid changes of 12 genes encoding target antigens for
CPS-induced antibodies as previously described [16].
With the exception of EIF3A, all examined proteins
showed amino acid changes in either NF135.C10 or
NF166.C8 with respect to NF54 (Table 2). Remarkably,
in contrast to their relative geographical distances, 11
out of 12 proteins in NF166.C8 and 8 out of 12 in
NF135.C10 were different compared to NF54.
Humoral and cellular markers of protection
Next, we tested a number of previously established
markers associated with exposure and homologous pro-
tection after CPS immunization [11, 33]. Figure 5 shows
the distribution of antibody-mediated inhibition of intra-
hepatic sporozoite development as well as the cellular
markers IFN-γ and granzyme B in CD4+ and CD8+ cells
Fig. 3 Neutralizing effect of CPS-induced antibodies on in vitro sporozoite functionality of homologous and heterologous P. falciparum strains.
(a) The number of primary human hepatocytes infected by homologous NF54 sporozoites in the presence of pre- or post-immunization plasma
in all (n = 24) CPS-immunized volunteers was determined by microscopy. (b) P. falciparum NF54, NF135.C10, or NF166.C8 sporozoites were pre-
incubated with pre- or post-immunization plasma from CPS-immunized volunteers and the percent inhibition of intra-hepatic development of
NF54, NF135.C10, or NF166.C8 was calculated for post- compared to pre-immunization plasma for each individual volunteer and presented as
squares (NF135.C10), triangles (NF166.C8), or circles (NF54). Data are shown as the mean of triplicate measurements for each individual volunteer
(a) or the median of all data points with an interquartile range (b). Differences in the percent inhibition of intra-hepatic development between
parasite strains were tested using one-way ANOVA with Bonferroni’s multiple comparison correction
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in all immunized volunteers undergoing heterologous
challenge. Remarkably, CD107a expression, particularly
in CD4+ T cells, was not increased as previously found
(data not shown) [11]; 2 out of 3 heterologous protected
volunteers were among the highest antibody-mediated
inhibitors of in vitro heterologous intra-hepatic develop-
ment (Fig. 5, orange square: NF135.C10-challenged;
green triangle: NF166.C8-challenged), with the highest
numbers of IFN-γ-producing CD8+ T cells against PfRBC.
The third protected volunteer showed only average neu-
tralizing antibody responses and IFN-γ-producing CD4+
and CD8+ T cells, but had a high number of granzyme B+
CD8+ T cells (orange upside down triangle: NF135.C10-
challenged). The group of NF135.C10 volunteers with a
prolonged pre-patent period did not distinguish them-
selves from the unprotected volunteers.
Discussion
This randomized, controlled clinical trial shows that
CPS immunization with P. falciparum NF54 sporozoites
induces modest sterile protection against challenge in-
fection with genetically distinct P. falciparum parasites.
In line with these clinical observations, antibodies in-
duced by NF54-CPS immunization inhibit intra-hepatic
development of both homologous and heterologous spo-
rozoites in vitro, but less efficiently inhibit heterologous
clones. P. falciparum-specific IFN-γ and granzyme B T
cell responses are also induced, corroborating previous
studies [11, 12], though unlike these studies, there was
no clear induction of CD107a responses. We have previ-
ously shown that PBMCs from NF54-exposed volunteers
have equivalent responses to homologous and heterol-
ogous PfRBC stimulation [24]. Here, volunteers pro-
tected against heterologous challenge showed relatively
high cellular and/or antibody responses. However, none
of these individual markers predicts protection.
In this study, heterologous protection was assessed
against a primary challenge infection in a double-blind
manner, strongly reducing any potential for bias. How-
ever, this study lacks the power to discriminate the low
protective efficacy seen in the NF166.C8 group with stat-
istical significance. Furthermore, although we chose to
test two geographically diverse heterologous strains, we
do not know how representative these are for the total
genetic diversity for P. falciparum in the field.
P. falciparum parasite strain diversity is a major
impediment to the development of effective, sterilizing
immunity [34]. Indeed, previous studies with single-
protein vaccines show that antigen polymorphisms
decrease vaccine efficacy [35–37]. However, genetic
diversity may be less challenging for whole sporozoite
vaccines representing a broader antigen repertoire that
could increase the chances for generating functional,
cross-strain immunity. In fact, immunization with
Fig. 4 Whole-genome sequencing shows genetic variations between study strains. Phylogenetic positions of the three P. falciparum strains (NF54,
NF135.C10 and NF166.C8) used in the study relative to other known P. falciparum strains. Whole-genome sequencing was used to infer relatedness to
P. falciparum strains from different areas [31]. Asian strains: THA Thailand (dark red), VIE Vietnam (light red), CAM Cambodia (orange); East African strains:
KEN Kenya; West African strains: GUI Guinea (light green), GHA Ghana (dark green); NF strains and 7G8 (blue)
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Table 2 Amino acid changes in genes involved in the humoral immune response after CPS immunization
Gene PfNF135.C10 PfNF166.C8
Sequence changes Protein changes Sequence changes Protein changes
PF3D7_1036400
LSA-1
6 4 14 9
PF3D7_0108300 Conserved unknown 21 12 15 8
PF3D7_1033100
AdoMetDC/ODC
10 9 9 8
PF3D7_0108300
MSP2
13 7 8 7
PF3D7_0304600
CSP
6 6
A98G
S301N
K317E
E318Q
N321K
A361E
7 7
S301N
K314Q
K317E
E318K
N321K
K322T
E357Q
PF3D7_0509400
RNApol
6 4 9 6
PF3D7_0630600
Conserved unknown
7 2 8 3
PF3D7_0502400
MSP8
2 1 4 3
PF3D7_1147800
MAEBL
2 0 3 1
PF3D7_0703700
Conserved unknown
0 0 1 1
PF3D7_0829000
Conserved unknown
0 0 1 1
PF3D7_1212700
EIF3A
1 0 1 0
Alterations in gene and protein sequences, based on whole genome sequencing, for 12 genes from NF135.C10 and NF166.C8 were compared to NF54. Single
nucleotide polymorphisms and small insertions/deletions are shown together as sequence changes with expected changes in the in silico-translated protein
sequence (counting altered amino acids). Changes in CSP protein sequence are indicated with single-letter amino acid code
Fig. 5 Analysis of in vitro intra-hepatic sporozoite development inhibition by CPS-induced antibodies, cellular responses and protection status
in vivo. CPS-induced antibody-mediated inhibition of in vitro challenge strain intra-hepatic development and cytotoxic and cytokine-producing T
cell responses to NF54-infected erythrocytes are shown. The 10th and 90th percentile of each response in all (n = 19) CPS-immunized volunteers
that received a heterologous challenge infection are shown as grey box-and-whisker plots. The green triangle represents 1 out of 9 CPS-
immunized volunteers sterilely protected against NF166.C8 challenge infection, while the orange square and upside down triangle represent the
2 out of 10 CPS-immunized volunteers with sterile protection against NF135.C10 challenge infection
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radiation-attenuated sporozoites by 1000 mosquitoes
[38] or with a total of 1.35 × 106 sporozoites adminis-
tered intravenously [39] has been shown to induce 80%
protection against challenge with the heterologous chal-
lenge strain 7G8 (IMTM-22 isolate from Brazil) at
3 weeks post-immunization, rapidly waning to only 10%
protection at 24 weeks [38, 39]. Doubling the dose of
intravenous sporozoite immunization to a total of 2.7 ×
106 showed an adjusted 53% efficacy against 7G8 at
33 weeks [18]. These data indicate that induction of
heterologous protection requires substantial high
immunization dosages, which puts constraints on
vaccine manufacturing and costs. In contrast, the CPS
regimen shows a 10- to 20-fold higher efficiency for
homologous protection, likely because volunteers are ex-
posed to the full pre-erythrocytic cycle and the initial
phase of the blood stage [40]. Previously, 2 out of 13
NF54-CPS-immunized volunteers receiving a sub-
optimal immunization dose were protected against a re-
challenge infection with NF135.C10 at 14 months after
the last immunization [19]. Both studies with radiation-
attenuated and CPS immunization showed higher hom-
ologous than heterologous protective efficacy. However,
none of these studies used an immunization regimen
sufficient for more than 90% homologous protective effi-
cacy. The current study is the first randomized, controlled
trial with a whole sporozoite immunization regimen suffi-
cient for complete homologous protection, testing primary
heterologous challenge infection 18 weeks after the last
immunization [11].
Despite 100% protection against homologous chal-
lenge, we obtained only a modest 10–20% protection
against heterologous strains. The observed difference in
protection against homologous and heterologous infec-
tions may be explained by various factors. (1) Unequal
distribution of induced immune responses between
study groups; however, anti-CSP antibody titers show a
clear consistency and similarity between study groups.
(2) Differences in numbers of inoculation sporozoites or
stringency of the challenge infection. The former is un-
likely as mosquito salivary gland infections were similar
between the generated strain batches (Additional file 2:
Table S2). As NF135.C10 and NF166.C8 show higher
sporozoite infectivity compared to NF54 [25], it may be
more difficult to protect against the NF135.C10 and
NF166.C8 clones. However, intra-hepatic sporozoite de-
velopment of NF135.C10 and NF166.C8 was equipo-
tently inhibited by a functional anti-CSP mAb, 2A10
(Additional file 2: Figure S2; IC50 concentrations of
2.5 μg/mL (95% CI 0.58–11 μg/mL), 3.5 μg/mL (95% CI
1.1–11 μg/mL), and 0.88 μg/mL (95% CI 0.26–2.9 μg/
mL)), which makes this explanation less likely. (3) Gen-
etic variation between the challenge parasites, shown to
be considerable with amino acid changes in either
NF135.C10 or NF166.C8 in 11 out of 12 target proteins
for CPS-induced antibodies [16]. We consider decreased
immune efficacy against genetically diverse parasite
strains as the most likely explanation for the modest
protection against heterologous parasites.
Since 3 out of 19 volunteers with sterile protection
against heterologous challenge tended to show more po-
tent responses to previously identified immune markers
[11, 15, 33], decreased efficacy against heterologous
parasites may be overcome by stronger immune re-
sponses. Improvement of the strength of cellular and
antibody responses may be achieved by altering
immunization regimens. For instance, this may be
achieved by increasing the immunization liver-stage
antigen load by raising the NF54 sporozoite
immunization dose, as has been done with radiation-
attenuated sporozoites [18, 41]. Alternatively, increased
liver-stage infectivity with a parasite such as NF135.C10
likely increases the antigen load without the need to in-
crease the number of sporozoites administered. A mix-
ture of parasite strains or sequential immunizations with
different strains are alternative options, but will compli-
cate the product manufacturing or its practical applica-
tion. The latter approach might be more efficient, as
heterologous sporozoites would evade strain-specific
neutralizing immunity, thereby increasing the liver para-
site burden at second and third immunizations. These
studies should aim to find the optimal balance between
the desired induction of cross-stage immunity and the
related adverse events that may occur. Taken together,
our findings highlight the need to further explore the
immunological basis of cross-strain protection against P.
falciparum in order to improve existing whole-
sporozoite immunization strategies.
Conclusions
These data demonstrate that, despite providing complete
protection against homologous challenge infection, CPS
immunization with the NF54 strain provides only mod-
est sterile protection against the genetically distinct
NF135.C10 and NF166.C8 clones. Our immunological
and parasite sequencing data suggest that genetic vari-
ation between the strains reduces the efficiency of anti-
bodies to block heterologous parasites. Since protected
volunteers tended to be higher immune responders, this
study underscores the need for whole sporozoite vaccin-
ation regimens to increase the height or breadth of im-
mune responses to achieve heterologous protection.
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Immunofluorescent analysis of P. falciparum-infected primary human
hepatocytes (S4). In vitro PBMC restimulation with PfRBCs and flow
cytometry staining (S5) [11, 12, 14, 17, 42]. (DOCX 20 kb)
Additional file 2: Figure S1. First-wave parasitemia after challenge.
Parasitemia on day 7 post-challenge in immunized (open circles) and
control (closed circles) volunteers. The line and error bars show the
geometric mean and 95% CI interval. Figure S2. Inhibition of in vitro
homologous and heterologous intra-hepatic sporozoite development
in primary human hepatocytes by mAb 2A10. P. falciparum NF54 (blue),
NF135.C10 (orange) and NF166.C8 (green) sporozoites in the presence
of 10% heat-inactivated naive human control serum were pre-incubated
with 3-fold serial dilutions of the 2A10 monoclonal antibody (0.027–
20 μg/mL), targeting the repeat region of the circumsporozoite protein
(CSP), and added to primary human hepatocyte cultures. Six days post-
infection, the number of P. falciparum-infected hepatocytes was assessed
as described in Additional file 1: S4 and S5. Figure S3. Amino acid
changes in CSP. Table S1. Whole-genome sequencing statistics. Table S2.
Mosquito salivary gland infectivity and sporozoite load of the three clones.
Mean mosquito salivary gland infectivity and sporozoite load determined
1 day prior to challenge infection by dissecting a sample of 10 mosquitoes
per strain. (DOCX 427 kb)
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